Compare VYGR & LTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | LTRX |
|---|---|---|
| Founded | 2013 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Communications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 237.4M |
| IPO Year | 2015 | 2000 |
| Metric | VYGR | LTRX |
|---|---|---|
| Price | $3.81 | $6.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $16.50 | $6.50 |
| AVG Volume (30 Days) | 511.1K | ★ 798.7K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,135,000.00 | ★ $122,923,000.00 |
| Revenue This Year | $34.04 | $1.12 |
| Revenue Next Year | $7.92 | $15.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.65 | $2.12 |
| 52 Week High | $5.55 | $8.24 |
| Indicator | VYGR | LTRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 62.37 |
| Support Level | $3.71 | $6.10 |
| Resistance Level | $4.39 | $8.24 |
| Average True Range (ATR) | 0.27 | 0.35 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 40.23 | 92.57 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.